479 related articles for article (PubMed ID: 14716740)
21. BPH treatment: urodynamic preoperative assessment and evaluation.
Nordling J; Nielsen K
Arch Esp Urol; 1994 Nov; 47(9):838-46. PubMed ID: 7530939
[TBL] [Abstract][Full Text] [Related]
22. [Incidence of the form and caliber of urethral resistance. Evaluation for a normal masculine urethra and in cases of obstruction due to prostatic hypertrophy].
Glémain P; Cordonnier JP; Bochereau G; Baron M; Le Normand L; Buzelin JM
Prog Urol; 1993 Dec; 3(6):995-1015; discussion 1006-8. PubMed ID: 7508314
[TBL] [Abstract][Full Text] [Related]
23. The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation.
Cho KS; Kim J; Choi YD; Kim JH; Hong SJ
Med Hypotheses; 2008; 70(3):532-5. PubMed ID: 17761390
[TBL] [Abstract][Full Text] [Related]
24. Effect of urethral compliance on the steady state p-Q relationships assessed with a mechanical analog of the male lower urinary tract.
Mijailovich SM; Sullivan MP; Yalla SV; Venegas JG
Neurourol Urodyn; 2007; 26(2):234-46. PubMed ID: 17039462
[TBL] [Abstract][Full Text] [Related]
25. Impact of different sized catheters on pressure-flow studies in patients with benign prostatic hyperplasia.
Klingler HC; Madersbacher S; Schmidbauer CP
Neurourol Urodyn; 1996; 15(5):473-81. PubMed ID: 8857615
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis and hormonal milieu in ductal system of normal prostate and benign prostatic hyperplasia.
Xia SJ; Xu CX; Tang XD; Wang WZ; Du DL
Asian J Androl; 2001 Jun; 3(2):131-4. PubMed ID: 11404798
[TBL] [Abstract][Full Text] [Related]
27. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of urodynamic findings and voiding habits in patients with concomitant benign prostatic hyperplasia and detrusor overactivity presenting with or without the symptom of urgency.
Tong YC
Urol Int; 2007; 78(3):219-25. PubMed ID: 17406130
[TBL] [Abstract][Full Text] [Related]
29. Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum.
Bernoulli J; Yatkin E; Konkol Y; Talvitie EM; Santti R; Streng T
Prostate; 2008 Sep; 68(12):1296-306. PubMed ID: 18500685
[TBL] [Abstract][Full Text] [Related]
30. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey.
Tubaro A; La Vecchia C;
Eur Urol; 2004 Jun; 45(6):767-72. PubMed ID: 15149750
[TBL] [Abstract][Full Text] [Related]
31. The soy effect in the disease models of nonbacterial prostatitis and obstructive voiding.
Yatkin E; Streng T; Kauppila ML; Bernoulli J; Saarinen N; Santti R
Exp Biol Med (Maywood); 2007 May; 232(5):674-81. PubMed ID: 17463164
[TBL] [Abstract][Full Text] [Related]
32. Role of angiogenesis in bladder response to partial outlet obstruction.
Levin R; Chichester P; Levin S; Buttyan R
Scand J Urol Nephrol Suppl; 2004; (215):37-47. PubMed ID: 15545195
[TBL] [Abstract][Full Text] [Related]
33. A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy.
Broderick GA; Longhurst PA; Juniewicz PE; Wein AJ; Levin RM
World J Urol; 1994; 12(5):245-8. PubMed ID: 7532514
[TBL] [Abstract][Full Text] [Related]
34. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study.
Koritsiadis G; Stravodimos K; Mitropoulos D; Doumanis G; Fokitis I; Koritsiadis S; Constantinides C
BJU Int; 2008 Jun; 101(12):1542-6. PubMed ID: 18294304
[TBL] [Abstract][Full Text] [Related]
35. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
Füllhase C; Soler R; Gratzke C; Brodsky M; Christ GJ; Andersson KE
BJU Int; 2010 Jul; 106(2):287-93. PubMed ID: 19888972
[TBL] [Abstract][Full Text] [Related]
36. Differences in the effects of estradiol on dihydrotestosterone induced prostatic growth of the castrate dog and rat.
Ehrlichman RJ; Isaacs JT; Coffey DS
Invest Urol; 1981 May; 18(8):466-70. PubMed ID: 7228581
[TBL] [Abstract][Full Text] [Related]
37. The chimpanzee as a model of human benign prostatic hyperplasia.
Steiner MS; Couch RC; Raghow S; Stauffer D
J Urol; 1999 Oct; 162(4):1454-61. PubMed ID: 10492237
[TBL] [Abstract][Full Text] [Related]
38. Role of growth factors in benign prostatic hyperplasia.
Lawson RK
Eur Urol; 1997; 32 Suppl 1():22-7. PubMed ID: 9218939
[TBL] [Abstract][Full Text] [Related]
39. Urodynamics in benign prostatic hyperplasia (BPH).
Schäfer W
Arch Ital Urol Androl; 1993 Dec; 65(6):599-613. PubMed ID: 7508790
[TBL] [Abstract][Full Text] [Related]
40. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Isaacs JT; Coffey DS
Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
